Considering the high prevalence of RAS point mutations in human tumors and the responsive role of BCL6 in KRAS oncogenic signaling, BCL6 inhibition may improve antitumor activity as a widely applicable approach in cancer therapy. This evidence concerns the gene KRAS and cancer.